Member Info for Gord_1

BS from today's RNS:

"termination of Previous Line of Credit : The Company and Skylake have agreed to terminate the former line-of-credit facility. That facility was structured for a discontinued digital-asset strategy and is no longer aligned with the Company's regulated gold-streaming and treasury focus."

Real Situation which is not difficult to work ou:

"termination of Previous Line of Credit : Me (Sath) and Me (Sath) have agreed to terminate the former line-of-credit facility which was really never there. That facility was BS and structured to pump up the market and SP so that Me (Sath) and my buddies could flip our shares we acquired in June at your expense."

Con artist !

"£127,450 was via Subscription by HNW sophisticated investors"

What this really means = Me and my mates will Flip into any SP rise ( like we did on the last raise last June) because we are so up our own a**se's. I'll tell the market BS about £2M investment @2p or that shares will also be issued at a much higher price today to help drive the price up so we can then flip. Con artist !

Buy in at 1.5 and you can't even sell at 1.3......NT to sell sadly which is never a good sign. The interview wasn't great, just more fluff about jam tomorrow when these items should have been resolved today. Licence timescales, Diamond revenues, Sand revenues. If they needed to purify the sand more then surely this should have been done earlier this year, also if they want to be able to get better grade diamonds then again earlier this year. As for the new extended licence....its been over a year from submission....?

AZN is becoming a more likely candidate then - thanks for the info . Buy and wait at these low levels ....and looks like someone is also loading up today I notice.

Frankie - Sorry for your loss. I would not trust a word that comes out of that con man Sath.

Deal with AZN on the cards?

Just note guys that any upside from this will be sold into by a warrant agreement that was never highlighted before until June this year. ....so why would Seth fund "£2M @ 2p per share when others can get them @ 0.23p ? . Its been a pump and dump all along by the BoD.

Extract from the agreement never disclosed prior:

Furthermore, the Company has received notice from Catalyse Capital Ltd and Tracarta Ltd ("Warrant Holders") that under the terms of the Warrant Instrument, relating to the funding announced on 30 September 2024, that the warrants will now reset to an exercise price of £0.0023 per share with the maturity on 30 September 2027 being unchanged. The warrant reset will result in the Warrant Holders now holding 93,755,435 warrants ("Restricted Warrants") each after the distribution described below.

Another shorter who is trying to cause fear. Those who support OBD are not ramping , just stating facts: Medical validation is the process of establishing objective evidence that a medical device, software, or process consistently produces a safe and effective result that meets the needs and requirements of its intended users and purpose. It ensures that the product performs reliably under actual or simulated clinical conditions. So the PSA test alone with low accuracy is medically validated causing further issues. !

AI Results on medical validation :

The PSA test is medically validated as a tool for monitoring existing prostate cancer, following up on symptoms, and aiding in the diagnostic pathway when used in conjunction with other tests like a digital rectal exam (DRE) or MRI. However, its use for routine population-wide screening for asymptomatic men is highly controversial among medical professionals and health organizations due to significant limitations and potential harms.

The EpiSwitch Prostate Screening (PSE) test is medically AND clinically validated through multiple studies and is available for use in the US and UK. It is a blood test designed to work alongside the standard PSA test to improve accuracy in detecting prostate cancer and help patients avoid unnecessary biopsies.

Here are key details regarding its validation:

Clinical Studies and Peer Review: The test was developed by scientists at Oxford University and clinically validated by clinician scientists from Imperial College London and the University of East Anglia. The results from these studies have been published in peer-reviewed medical journals such as Cancers.

High Accuracy: When combined with the standard PSA test, the EpiSwitch PSE test demonstrated 94% accuracy in identifying the presence or absence of prostate cancer in initial studies. Biopsy Avoidance: Real-world evidence studies have shown that using the PSE test as a triage tool could help up to 80% of patients safely avoid an immediate, invasive biopsy.

Dug - just to add ...an AI search has come back with below , which contradicts the nonsense you are posting:

Also note the NHS wasted £B on stuff such as PPE equipment that were useless.....but when it comes to technologies like this that will save lives...they have their heads in the sands. As you can probably tell I'm a bit concerned that you keep blaming Ross and also making false claims when the real problem here is the NHS decision makers.

AI response to your claim : The NHS CANNOT ADOPT A MEDICALLY UNVALIDATED TEST

The EpiSwitch PSE test IS MEDICALLY VALIDATED through a number of clinical studies and real-world evidence, demonstrating high accuracy in identifying prostate cancer risk. It is available for clinical use in the US and UK private sector; however, it is not yet part of standard national screening programs like the NHS.

Key Validation Details

Clinical Studies & Peer Review: The test was developed by scientists at the University of Oxford and clinically validated by clinician scientists from Imperial College and the University of East Anglia. The results have been published in peer-reviewed journals, including Cancers and the Journal of Translational Medicine, presenting data from real-world observational studies.

High Accuracy: When combined with the standard PSA test, the EpiSwitch PSE test has demonstrated an overall accuracy of up to 94%. This is significantly higher than the PSA test alone, which is about 55% accurate.

CLIA Certification: In the US, the test is a laboratory-developed test (LDT) processed in a CLIA-certified (Clinical Laboratory Improvement Amendments) laboratory, which means it meets federal regulatory standards for clinical testing, though it is not reviewed or cleared by the FDA.

Biopsy Avoidance: Studies have shown that using the PSE test as a triage tool could help up to 80% of patients safely avoid unnecessary invasive prostate biopsies, a major limitation of current diagnostic pathways.

Insurance Coverage: In the UK, the test is covered by Bupa UK insurance. In the USA, the test is covered by insurance programs.

Dug - as you have kindly called out other board members comments, you appear to be a shorter or want to destroy other peoples investments. So to give a balanced view could you explain a little more:

1) "They have taken the test 'worldwide' The US was the market of choice under Burrows and the majority of his board and senior management team were based there. He had labs in the US and Asia ( a ridiculous waste of shareholders money)". -

My view - Is this Ross view also or has this now been addressed through cost saving measures. Is this still the strategy of the current BoD ?

2) "The NHS CANNOT ADOPT A MEDICALLY UNVALIDATED TEST. So suggestions that they are 'blind to it' is just nonsense."

My response - Why cant the NHS validate this test when Bupa do? Bupa MD response to this test recently - We're pleased to partner with Oxford BioDynamics to cover the advanced EpiSwitch PSE test. The PSE provides a more accurate path to diagnosing prostate cancer, where getting an early diagnosis can make the disease nearly completely survivable. Offering the PSE and CiRT tests reflects our commitment to leverage the most advanced precision medicine testing to provide doctors with the tools they need to make informed decisions."

3) Your comment - "Equally OBD do not have the financial or human resources to run their own screening programme".

My response - Whilst I appreciate OBD do not themselves have the financial or human resources, partners such as Bupa do, thus I think your missing the point. Is it such a bad idea that OBD partners do a national campaign to highlight that they provide such tests to customers in the absence of the NHS in doing so. ?

4) Your comment - "I suppose I should expect such remarks and blame myself for investing in an AIM company".

My response - You seem to feel your of higher intelligence to others on here. I suggest you either sell up or act a little more positive with substance to back up your false claims....unless you are shorting this stock you can be as negative as much as you want but be careful of false claims.

If national screening was approved however excluded OBD....that would cost the NHS significantly in false results and biopsy's etc. IMO OBD should run their own national campaign.......perhaps include an annual test with your private health care plan. If they can get volume = reduced cost of the test. All possibilities should be explored by the board given the NHS appear to be blind to the cost savings this test could provide. Take the initiative whilst this subject is being highlighted in the public domain. Even get one of the national newspapers to run a campaign on OBD whilst this is a hot subject. Pull your finger our Ross and take some action for the salary you are drawing. Its not rocket science to understand where their is mess there is an opportunity.

SATS are in the poop sadly with BTC debt however the only positive ..........which is good for Astrid as they state that their only positive is:

"Higher utilisation of the Tao subnet and increasing revenues with plans for further expansion of operating businesses"

This endorses Astrid's current strategy

Interesting comment within SATS RNS announcement today:

Higher utilisation of the Tao subnet and increasing revenues with plans for further expansion of operating businesses

I bet they also wish they had sold the BTC and moved all into TAO !

Ditto ....its about time something good happens here.

Under NDA they will not mention who they are...sadly. Bit disappointed that a structured time plan has not been pulled together if 10 pharma's are engaged.....ie

1) Diligence period will start at x and be closed by y.

2) Formal partnership bids submitted by X

3) Bid partnership review period.

4) Final partner discussions

5) partnership announcement.

All we have from the CEO is no structure to a partnership deal, and that we are taking to various partners and it may happen in 2026, hence the SP decline.

A more formal structure should have been put into force if 10 Pharma's are all involved as they will all be confused as hell about who/what/when/how they should engage with internally to make the decisions, and what the others might be doing also.

It smells a bit tbh .

Https://taostats.io/subnets

Looking good ! Near the top over the month and our Subnet MC is growing :-)

Interesting comment from the experts: "We see Bittensor 2026 as a similar opportunity to pre-IPO Google or Bitcoin before it’s first halving, when the price was $13 and nobody had a clue what it was"

Why is halving important?...(.i'm a dummy investor)

IMO , Tim used the market to get the message out to the major players that they had something unique that was going to disrupt their existing ££££B food-chain. By suggesting a deal was imminent may have been a strategy to grab their attention before they lost out. They may have just been talking initially to mid players. If P140 is as good as they say it is, a major player may now have entered the room, thus it may take a little more time to pull the deal together , hence the delay.....I can only think that was the reason..Gla

Its clear that the Ghana government have not been exactly good hosts for foreign investment. False Tax claims, withholding money etc. Tullow has done its bit to mitigate against this but I think a game is being played. Look at the damage your causing Mr Ghana Government when we are trying to invest in your country........hence the fairly bleak Nov trading statement. If the trading statement was positive, it would allow the Ghana government to continue with their games. This situation is being manipulated to provide Tullow with the best outcome.......repayment of monies owed, more wells producing and renegotiated bonds. I might be wrong but this is why i have invested here for the upside. ...Gla

QQ - Why did they pay back and cancel the RCF before any other debt. Surely they had a reason ....perhaps that they knew that Bonds would be renegotiated and dealt with ? I think this will come good as the Ghana government and Kos would not be able to survive without Tullow's infrastructure . Also another new well is coming online soon ( 2nd of 5) and the first contributed ~ 10K....so big upswing from here if the bondholders play ball....imo